@article{283a180405ce4213860401109eb1f259,
title = "Quantifying the return of headache in triptan-treated migraineurs: An observational study",
abstract = "To improve understanding of secondary treatment failure in migraine patients, we evaluated 'headache return' as a novel endpoint to assess returning headaches according to their severity, expanding on current standard assessments of overall recurrence or relapse rates, in a six-month observational study of triptan-treated migraineurs. A total of 359 patients (91% female; mean age, 42.5 years) recorded data for 2168 headaches in electronic diaries. Two-thirds of headaches responded to triptan treatment (improved-to-mild or no pain two hours post-dose); 34% of headaches had a pain-free response. By 48 hours post-dose, 19% of all responding headaches returned; 24% of headaches achieving a pain-free response returned, predominantly to mild pain. More severe baseline headache, short duration since diagnosis of migraine, and female gender were associated with increased likelihood of headache return. Treatment satisfaction declined with increasing severity of headache return, demonstrating the value of assessing headache return by severity to fully evaluate its impact.",
keywords = "headache return, migraine, observational study, triptan",
author = "Fred Sheftell and Mary Almas and Randall Weeks and Mathew, {Ninan T.} and Verne Pitman and Lipton, {Richard B.}",
note = "Funding Information: This study was sponsored by Pfizer, Inc. Drs Sheftell, Lipton and Matthew have received research grants from Pfizer. Drs Weeks and Matthew have received honoraria from Pfizer (not relating to development of this manuscript). Drs Pitman and Almas are employees of Pfizer, and Dr Pitman has stock in Pfizer. Editorial assistance in preparing the manuscript was also funded by Pfizer. Funding Information: Dr Lipton is funded by National Institutes of Health grants PO1AG03949, PO1AG027734 RO1AG25119 and is a mentor for K23AG030857, K23NS05140901A1 and K23NS47256. He receives research funding from the National Headache Foundation and the Migraine Research Fund. He serves as an editorial board member for Neurology and Cephalalgia and as senior advisor to Headache . He holds stock options in Neuralieve, Inc., and Minster, Inc., and consults for, conducts studies funded or has received lecture honoraria from Advanced Bionics, Allergan, Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Endo, GlaxoSmithKline, Johnson & Johnson, Kowa, Minster, Merck, Neuralieve, OrthoMcNeil and Pfizer. ",
year = "2010",
month = jul,
doi = "10.1177/0333102409354390",
language = "English (US)",
volume = "30",
pages = "838--846",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "7",
}